溪黄草对代谢综合征患者血栓前状态及前炎性状态标志物的作用

目的探讨溪黄草对代谢综合征患者血栓前状态及前炎性状态标志物的作用。方法选择代谢综合征血栓前状态及前炎性状态标志物异常患者100例,按区组随机法分成2组,每组50例,健康对照组50例。Ⅰ组和Ⅱ组均用溪黄草5g加凉开水60mL,保持50℃～60℃浸泡1h后饮服,连服28d,Ⅰ组每日服1次;Ⅱ组每日服2次,上下午各1次。Ⅰ组和Ⅱ组分别于治疗前1d、治疗后29d查ET、VwF、GMP-140、DD、hs-CRP和肝肾功能,治疗后第7、14、21天查肝肾功能。对照组于入选时查ET、VwF、GMP-140、DD、hs-CRP。2个治疗组治疗前分别与空白对照组比较,2个治疗组治疗前后分别比较、组间分别比较。结果①治疗组Ⅰ和治疗组Ⅱ治疗前的ET、VwF、GMP-140、DD及hs-CRP分别与空白对照组对比,差异有显著性(P均﹤0.01);②治疗组Ⅰ和治疗组Ⅱ治疗前后的ET、VwF、GMP-140、DD及hs-CRP对比,差异有统计学意义(P均﹤0.05);③治疗组Ⅰ与治疗组Ⅱ治疗后组间的ET、VwF、GMP-140、DD及hs-CRP对比,差异无统计学意义(P均﹥0.05)。结论溪黄草可改善代谢综合征患者血栓前状态及前炎性状态。目的探讨溪黄草对代谢综合征患者血栓前状态及前炎性状态标志物的作用。方法选择代谢综合征血栓前状态及前炎性状态标志物异常患者100例,按区组随机法分成2组,每组50例,健康对照组50例。Ⅰ组和Ⅱ组均用溪黄草5g加凉开水60mL,保持50℃～60℃浸泡1h后饮服,连服28d,Ⅰ组每日服1次;Ⅱ组每日服2次,上下午各1次。Ⅰ组和Ⅱ组分别于治疗前1d、治疗后29d查ET、VwF、GMP-140、DD、hs-CRP和肝肾功能,治疗后第7、14、21天查肝肾功能。对照组于入选时查ET、VwF、GMP-140、DD、hs-CRP。2个治疗组治疗前分别与空白对照组比较,2个治疗组治疗前后分别比较、组间分别比较。结果①治疗组Ⅰ和治疗组Ⅱ治疗前的ET、VwF、GMP-140、DD及hs-CRP分别与空白对照组对比,差异有显著性(P均﹤0.01);②治疗组Ⅰ和治疗组Ⅱ治疗前后的ET、VwF、GMP-140、DD及hs-CRP对比,差异有统计学意义(P均﹤0.05);③治疗组Ⅰ与治疗组Ⅱ治疗后组间的ET、VwF、GMP-140、DD及hs-CRP对比,差异无统计学意义(P均﹥0.05)。结论溪黄草可改善代谢综合征患者血栓前状态及前炎性状态。

Effect of isodon serra (maxim) kudo on the markers of prekronbotic state and preimflammation state in metabolize syndrome

Objective To evaluate the effect of isodon. serra (maxim) kudo on the markers of prekronbotic state and preimflammation state in Metabolize syndrome. Methods 100 patients with abnormal markers of prekronbotic state and preimflammation state in metabolize syndrome were randomly divided into treatment groupⅠ (groupⅠ, n=50) and treatment groupⅡ(groupⅡ, n=50). Healthy controls (groupsⅢ, n=50) without treatment. The patients in groupⅠand groupⅡ drinked with isodon. serra(maxim) kudo( 5 g soaked in 50-60 degrees 50 ml water for 60 minutes) for 28 days(GroupⅠq.d, GroupsⅡ b.i.d). The plasma ET, VwF, GMP-140, DD, hs-CRP, ALT, AST and BNU of the groupⅠandⅡ were detected in the day before treatment and 29th day after treatment. ALT, AST and BUN were detected in 7th,14th, and 21th day after treatment. Results ① Remarkable difference was found on the levels of plasma ET,VwF,GMP-140,DD and hs-CRP in groupⅠand Ⅱ before treatment compared with those in groups Ⅲ (P﹤0.01). ② Remarkable difference in groupⅠand Ⅱ was found on the levels of plasma ET, VwF, GMP-140, DD and hs-CRP before treatment compared with those after treatment (P﹤0.05). ③ No difference was found on the levels of plasma ET,VwF,GMP-140,DD and hs-CRP after treatment between groupⅠandⅡ (P﹥ 0.05). Conclusion Isodon. serra (Maxim)Kudo can influence the markers of prekronbotic state and preimflammation state in metabolize syndrome.